Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  WEE1 inhibitor MK-1775
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-17 of 17 for your search:
Start Over
WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI
Protocol IDs: NCI-2014-00547, ADVL1312, UM1CA097452, NCT02095132
Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: M10MKO / MK1775-009, NCT01164995
NCI-MPACT: Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 130105, 13-C-0105, NCT01827384
A Study of Cisplatin With or Without MK-1775 in Squamous Cell Cancer of the Head and Neck
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: PHL-088 / NCI 9416, NCT01935037
A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D6011C00001, NCT02087176
Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D6011C00002, NCT02087241
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00620, NCI 9568, PHL-093, 9568, N01CM00032, NCT02101775
A Study of AZD1775 + Chemotherapy Versus Chemotherapy in Patients to Treat Ovarian, Fallopian Tube, Peritoneal Cancer.
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: D6010C00004, NCT02272790
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy
Phase: Phase II
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: 2014-04-127, NCT02448329
MK-1775 for Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 130032, 13-C-0032, NCT01748825
WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00858, ABTC 1202, UM1CA137443, NCT01849146
A Dose Escalation Trial of Wee1 Inhibitor MK1775
Phase: Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: HUM00079048, UMCC 2013.xxx, NCT01916551
WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 37 months to 21 years
Sponsor: NCI
Protocol IDs: NCI-2013-01602, COG-ADVL1217, ADVL1217, UM1CA097452, NCT01922076
A Study of MK-1775 in Combination With Cisplatin and Radiation in Cervical Cancer
Phase: Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: PHL-087 / NCI 9407, NCT01925326
Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D6011C00003, NCT02341456
WEE1 Inhibitor MK-1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2015-00257, MCC-12-07328, 9853, N01CM62208, P30CA076292, NCT02381548
A Phase 0 Study of AZD1775 in Recurrent GBM Patients
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BBTRC 001, NCT02207010
Start Over